Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

TNF Stabilizes Inflammatory RNA in Synoviocytes

Lara C. Pullen, PhD  |  August 14, 2017

Previous research has indicated that mitogen-activated protein kinases (MAPKs) play an important role in the regulation of mRNA stability by phosphorylating RNA-binding proteins. The researchers found that this was also the case for TNF-induced stabilization. The TNF-induced stabilization was MAPK-dependent and involved several genes with pathogenic potential, such as IL6, CXCL1, CXCL3, CXCL8/IL8, CCL2, and PTGS2. Thus, TNF appears to induce a late transcriptional program that leads to the expression of gene products that stabilize mRNAs in a selective manner. Because a stable transcript would theoretically be able to support continuously rising expression even in the presence of very low or decreasing rates of transcription, the stabilization of mRNA by TNF can explain the discordance in kinetics between active transcription and total mRNA expression in patients with RA. In this way, TNF contributes to enhanced expression of inflammatory genes and the perpetuation of synovitis.


Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Loupasakis K, Kuo D, Sokhi UK, et al. Tumor necrosis factor dynamically regulates the mRNA stabilome in rheumatoid arthritis fibroblast-like synoviocytes. PLoS One. 2017 Jul 14;12(7):e0179762. doi:10.1371/journal.pone.0179762. eCollection 2017.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsRheumatoid Arthritis Tagged with:fibroblast-like synoviocytesRheumatoid Arthritis (RA)RNAtumor necrosis factor inhibitor

Related Articles

    Prevent Osteoporotic Fractures with a Fracture Liaison Service

    May 18, 2019

    Imagine leaving the hospital after suffering a heart attack without being treated for hypertension or being started on a beta blocker. What would we think of the hospital where patients are never educated about the relationship between treating hypertension and reducing myocardial infarction and stroke risk? Unfortunately, this happens every day with osteoporosis and fractures…

    TNF Blockade for SLE

    September 1, 2010

    Reckless approach versus missed opportunity?

    T Cells in Systemic Lupus Erythematosus

    August 1, 2011

    Progress toward targeted therapy

    Best Practices for Treating Non-Specific Low Back Pain

    December 16, 2015

    Low back pain (LBP) is one of the most common reasons for physician appointments. However, treatment results remain suboptimal, resulting in high rates of chronic pain, narcotic usage, surgery, depression and disability—all at great cost to individuals and the nation. One reason for this is the current practice of grouping all low back pain patients…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences